- Home
- INLX vs RNXT Comparison
INLX vs RNXT Comparison
Compare INLX & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INLX
- RNXT
- Stock Information
- Founded
- INLX 1996
- RNXT 2012
- Country
- INLX United States
- RNXT United States
- Employees
- INLX N/A
- RNXT N/A
- Industry
- INLX EDP Services
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- INLX Technology
- RNXT Health Care
- Exchange
- INLX Nasdaq
- RNXT Nasdaq
- Market Cap
- INLX 40.8M
- RNXT 40.7M
- IPO Year
- INLX N/A
- RNXT 2021
- Fundamental
- Price
- INLX $11.75
- RNXT $1.29
- Analyst Decision
- INLX
- RNXT Strong Buy
- Analyst Count
- INLX 0
- RNXT 2
- Target Price
- INLX N/A
- RNXT $7.50
- AVG Volume (30 Days)
- INLX 6.8K
- RNXT 724.7K
- Earning Date
- INLX 11-12-2025
- RNXT 11-12-2025
- Dividend Yield
- INLX N/A
- RNXT N/A
- EPS Growth
- INLX N/A
- RNXT N/A
- EPS
- INLX N/A
- RNXT N/A
- Revenue
- INLX $17,127,854.00
- RNXT $662,000.00
- Revenue This Year
- INLX N/A
- RNXT $2,895.35
- Revenue Next Year
- INLX $14.19
- RNXT $313.04
- P/E Ratio
- INLX N/A
- RNXT N/A
- Revenue Growth
- INLX N/A
- RNXT N/A
- 52 Week Low
- INLX $8.74
- RNXT $0.75
- 52 Week High
- INLX $16.50
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- INLX 55.67
- RNXT 54.48
- Support Level
- INLX $10.60
- RNXT $1.06
- Resistance Level
- INLX $11.10
- RNXT $1.15
- Average True Range (ATR)
- INLX 0.17
- RNXT 0.10
- MACD
- INLX -0.01
- RNXT -0.02
- Stochastic Oscillator
- INLX 67.25
- RNXT 56.16
About INLX Intellinetics Inc.
Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.